Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Katsuhiko Uesaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9983-1730; OpenAlex author ID A5019199908. Sources: OpenAlex.

Their work

Papers
71 (first author 3, last author 38)
Trials
0
Grants
0
Labs led
1
Collaborators
115
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: 3 papers · 2019: 4 papers · 2020: 9 papers · 2021: 9 papers · 2022: 9 papers · 2023: 7 papers · 2024: 2 papers · 2025: 4 papers · 2026: 11 papers

Papers 50 of 71

  1. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Last author DOI 10.1002/jhbp.70117↗
  2. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Last author DOI 10.1007/s00535-026-02413-5↗
  3. Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria. Co-author DOI 10.1007/s00595-025-03223-7↗
  4. Intraoperative decision-making for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis: Proposal of a pathology-based weighted risk … Last author DOI 10.1016/j.suronc.2026.102559↗
  5. Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy. Co-author DOI 10.1097/sla.0000000000007152↗
  6. Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. Co-author DOI 10.1245/s10434-025-18556-3↗
  7. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  8. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  9. Prognostic Significance of Radiological Adjacent Organ Invasion in Resectable Left-Sided Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19244-6↗
  10. ASO Author Reflections: Rethinking Resectability in Left-Sided Pancreatic Cancer-The Clinical Meaning of Radiological Adjacent Organ Invasion. Co-author DOI 10.1245/s10434-026-19394-7↗
  11. ASO Visual Abstract: Prognostic Significance of Radiological Adjacent Organ Invasion in Resectable Left-Sided Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19416-4↗
  12. Association Between the Degree of Arterial Contact Angle and Survival in Patients With Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1002/ags3.70052↗
  13. Clinical significance of resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis. Co-author DOI 10.1016/j.surg.2024.10.016↗
  14. Impact of Perioperative Hemoglobin A1c Levels on Survival Outcomes of Patients With Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1097/as9.0000000000000597↗
  15. Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases. Co-author DOI 10.1097/mpa.0000000000002485↗
  16. Predictive factors of actual 5-y recurrence-free survival after upfront surgery for resectable pancreatic cancer: Exploration of patients who did not require n… Last author DOI 10.1002/ags3.12834↗
  17. Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. Co-author DOI 10.1093/bjs/znae059↗
  18. Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. Co-author DOI 10.1002/ags3.12636↗
  19. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Last author DOI 10.1002/jhbp.1353↗
  20. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology. Last author DOI 10.1007/s00423-023-02906-4↗
  21. Corrigendum to Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer: [Surgery. 2022;172(6):1776-81, DOI: 10… Last author DOI 10.1016/j.surg.2023.05.001↗
  22. Characterization of pancreatic cancer with ultra-low tumor mutational burden. Co-author DOI 10.1038/s41598-023-31579-8↗
  23. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer. Last author DOI 10.1245/s10434-023-13564-7↗
  24. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Us… Last author DOI 10.1245/s10434-023-13629-7↗
  25. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Last author DOI 10.1002/cnr2.1507↗
  26. The prognostic impact of ABO blood type in pancreatic cancer: Relevance to adjuvant chemotherapy. Last author DOI 10.1002/jhbp.1152↗
  27. The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Last author DOI 10.1016/j.pan.2022.03.017↗
  28. Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer. Last author DOI 10.1016/j.surg.2022.09.025↗
  29. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Last author DOI 10.1097/sla.0000000000004535↗
  30. Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified? Last author DOI 10.1245/s10434-022-11624-y↗
  31. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Ven… Last author DOI 10.1245/s10434-022-11628-8↗
  32. ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologic… Last author DOI 10.1245/s10434-022-11639-5↗
  33. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated … Last author DOI 10.1245/s10434-022-11662-6↗
  34. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy. Last author DOI 10.1007/s00535-020-01730-7↗
  35. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s13304-020-00792-9↗
  36. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. Last author DOI 10.1016/j.pan.2021.08.009↗
  37. Histological Differentiation Is a Pivotal Prognostic Factor Associated With the Pattern of Recurrence Following Resection of Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001848↗
  38. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Co-author DOI 10.1111/cas.14914↗
  39. Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer. Last author DOI 10.1245/s10434-020-09066-5↗
  40. Clinical Implication of Node-negative Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-020-09543-x↗
  41. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. Last author DOI 10.1245/s10434-021-09593-9↗
  42. ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients. Last author DOI 10.1245/s10434-021-09660-1↗
  43. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus. Last author DOI 10.1007/s00423-020-01874-3↗
  44. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Last author DOI 10.1007/s00423-020-01970-4↗
  45. Middle segment-preserving pancreatectomy for multifocal pancreatic ductal adenocarcinoma located in the head and tail of the pancreas: a case report. Last author DOI 10.1093/jscr/rjaa383↗
  46. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000001513↗
  47. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Last author DOI 10.1111/cas.14258↗
  48. [Postoperative adjuvant chemotherapy for resectable pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.117.308↗
  49. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Co-author DOI 10.1186/s12885-020-07698-0↗
  50. Multiple Carcinomas and Intraepithelial Neoplasms in a Case of Familial Pancreatic Cancer: Rapid Morphological Changes in the Pancreatic Cyst and Pathological … Co-author DOI 10.2169/internalmedicine.3882-19↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryo Ashida · 45 shared papers, 2017–2026 · strength 7.93
  2. Teiichi Sugiura · 50 shared papers, 2011–2026 · strength 7.85
  3. Katsuhisa Ohgi · 39 shared papers, 2019–2026 · strength 7.15
  4. Yukiyasu Okamura · 33 shared papers, 2011–2026 · strength 4.02
  5. Mihoko Yamada · 18 shared papers, 2018–2026 · strength 3.37
  6. Yoshiyasu Kato · 10 shared papers, 2025–2026 · strength 2.74
  7. Takaaki Ito · 16 shared papers, 2017–2022 · strength 1.83
  8. Hirochika Toyama · 11 shared papers, 2019–2026 · strength 1.74
  9. Taisuke Imamura · 10 shared papers, 2019–2024 · strength 1.40
  10. Akira Fukutomi · 10 shared papers, 2016–2026 · strength 1.29
  11. Takumi Kitahama · 4 shared papers, 2026 · strength 1.14
  12. Soichiro Morinaga · 10 shared papers, 2016–2026 · strength 1.11
  13. Keiichi Ohshima · 5 shared papers, 2023–2026 · strength 1.00
  14. Akiko Todaka · 7 shared papers, 2019–2023 · strength 0.96
  15. Kenichi Urakami · 5 shared papers, 2018–2026 · strength 0.91
  16. Hidemasa Kubo · 5 shared papers, 2022–2025 · strength 0.87
  17. Kentaro Yamazaki · 5 shared papers, 2011–2025 · strength 0.85
  18. Atsuyuki Maeda · 6 shared papers, 2011–2026 · strength 0.85
  19. Narikazu Boku · 6 shared papers, 2016–2026 · strength 0.82
  20. Yuya Miura · 4 shared papers, 2022–2026 · strength 0.79
  21. Naoto Gotohda · 4 shared papers, 2019–2026 · strength 0.73
  22. Shinichiro Takahashi · 6 shared papers, 2017–2023 · strength 0.65
  23. Tomoko Norose · 3 shared papers, 2022–2026 · strength 0.59
  24. Jun Shibamoto · 2 shared papers, 2025–2026 · strength 0.52
  25. Motohiro Kojima · 5 shared papers, 2017–2022 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.